InVivo Therapeutics Holdings (FRA:04I) Debt-to-Equity : 0.00 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings Debt-to-Equity?

InVivo Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.00 Mil. InVivo Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.00 Mil. InVivo Therapeutics Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €8.36 Mil. InVivo Therapeutics Holdings's debt to equity for the quarter that ended in Sep. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for InVivo Therapeutics Holdings's Debt-to-Equity or its related term are showing as below:

FRA:04I' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.17 Med: 0.08 Max: 0.33
Current: 0.09

During the past 13 years, the highest Debt-to-Equity Ratio of InVivo Therapeutics Holdings was 0.33. The lowest was -0.17. And the median was 0.08.

FRA:04I's Debt-to-Equity is ranked better than
61.42% of 1081 companies
in the Biotechnology industry
Industry Median: 0.15 vs FRA:04I: 0.09

InVivo Therapeutics Holdings Debt-to-Equity Historical Data

The historical data trend for InVivo Therapeutics Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Debt-to-Equity Chart

InVivo Therapeutics Holdings Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.24

0.05

0.07

0.06

InVivo Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.10	0.06	0.06	0.07	-

Competitive Comparison of InVivo Therapeutics Holdings's Debt-to-Equity

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InVivo Therapeutics Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Debt-to-Equity falls into.

InVivo Therapeutics Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

InVivo Therapeutics Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.374	+	0.522)	/	14.864
	=	0.06

InVivo Therapeutics Holdings's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	8.356
	=	0.00

InVivo Therapeutics Holdings (FRA:04I) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

InVivo Therapeutics Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

InVivo Therapeutics Holdings (FRA:04I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NVIV:USA

Address

One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.invivotherapeutics.com

InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines